Want to see LPCN full AI Analyst Report?
Top Page
Lipocine
(NASDAQ:LPCN)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.00
▼(-3.85% Downside)
Action:Reiterated
Date:08/04/26
The score is primarily held down by weak financial performance (shrinking revenue, sizable losses, and continued negative free cash flow) and bearish technicals (price below key moving averages with negative MACD and weak RSI). Corporate events are a moderate positive due to pipeline visibility and leadership additions, but valuation support is limited given loss-making status and no dividend.
Positive Factors
Proprietary oral delivery & late‑stage asset
Owning a proprietary oral delivery approach and advancing LPCN 1154 through Phase 3 provides durable strategic optionality: it materially raises the probability of a regulatory path or partner interest, supports differentiation versus IV competitors, and can underpin sustainable market positioning if approved or partnered.
Negative Factors
Shrinking revenue and sizable losses
Declining top line alongside large, persistent net losses indicates weak commercial traction and poor operational leverage. Over months this compresses resources available for R&D and commercialization, increases dependence on external funding, and undermines the company’s ability to self‑fund pipeline advancement.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary oral delivery & late‑stage asset
Owning a proprietary oral delivery approach and advancing LPCN 1154 through Phase 3 provides durable strategic optionality: it materially raises the probability of a regulatory path or partner interest, supports differentiation versus IV competitors, and can underpin sustainable market positioning if approved or partnered.
Read all positive factors
Lipocine (LPCN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$17.48M
Dividend YieldN/A
Average Volume (3M)89.50K
Price to Earnings (P/E)―
Beta (1Y)0.36
Revenue Growth-45.52%
EPS Growth-94.82%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.87
Shares Outstanding8,244,253
10 Day Avg. Volume42,666
30 Day Avg. Volume89,504
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.02
Price to Sales (P/S)22.14
P/FCF Ratio-4.48
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside188.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.9
Revenue Forecast (FY)$776.40K
Lipocine Business Overview & Revenue Model
Company Description
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research ...
How the Company Makes Money
null...
Lipocine Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.57M | 1.98M | 11.20M | -2.85M | 500.00K | 16.14M |
| Gross Profit | 1.35M | -6.61M | 11.20M | -13.03M | -8.06M | 8.48M |
| EBITDA | -9.18M | -9.57M | 50.14K | -16.32M | -10.72M | -430.53K |
| Net Income | -11.85M | -9.63M | 8.35K | -16.35M | -10.76M | -634.40K |
Balance Sheet | ||||||
| Total Assets | 23.84M | 17.01M | 22.51M | 23.00M | 37.54M | 52.48M |
| Cash, Cash Equivalents and Short-Term Investments | 23.27M | 14.93M | 21.63M | 22.04M | 32.53M | 44.62M |
| Total Debt | 0.00 | 449.59K | 0.00 | 0.00 | 0.00 | 2.31M |
| Total Liabilities | 2.07M | 2.53M | 1.51M | 2.63M | 1.91M | 6.91M |
| Stockholders Equity | 21.77M | 14.48M | 21.00M | 20.37M | 35.63M | 45.57M |
Cash Flow | ||||||
| Free Cash Flow | -5.91M | -9.76M | -1.31M | -11.88M | -12.10M | -4.42M |
| Operating Cash Flow | -5.91M | -9.76M | -1.22M | -11.87M | -11.97M | -4.41M |
| Investing Cash Flow | -6.15M | 5.89M | 2.45M | 13.08M | 14.29M | -43.78M |
| Financing Cash Flow | 16.27M | 2.87M | 209.34K | 404.57K | -2.13M | 26.92M |
Lipocine Technical Analysis
Negative
2.08
Price Trends
2.27
Negative
3.08
Negative
4.58
Negative
Market Momentum
-0.07
Positive
41.70
Neutral
35.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LPCN, the sentiment is Negative. The current price of 2.08 is below the 20-day moving average (MA) of 2.23, below the 50-day MA of 2.27, and below the 200-day MA of 4.58, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 41.70 is Neutral, neither overbought nor oversold. The STOCH value of 35.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LPCN.
Lipocine Risk Analysis
Lipocine disclosed 61 risk factors in its most recent earnings report. Lipocine reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lipocine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $6.35M | -1.41 | -102.06% | ― | -100.00% | 62.88% | |
46 Neutral | $69.55M | -2.43 | -53.86% | ― | -20.00% | 75.26% | |
46 Neutral | $12.27M | -0.80 | -5456.14% | ― | -100.00% | 59.83% | |
45 Neutral | $17.48M | -1.08 | -66.69% | ― | -45.52% | -94.82% |
* Healthcare Sector Average
LPCN
Lipocine
2.13
-0.95
-30.84%
IBIO
Ibio
1.46
0.84
134.73%
PULM
Pulmatrix
1.66
-3.82
-69.71%
BCDA
BioCardia
0.91
-0.90
-49.72%
ASBP
Aspire Biopharma Holdings
7.04
-417.40
-98.34%
Lipocine Corporate Events
Business Operations and StrategyExecutive/Board Changes
Lipocine Appoints Industry Veteran Grissinger to Board
Positive
Aug 3, 2026
On August 3, 2026, Lipocine Inc., a biopharmaceutical firm specializing in oral drug delivery, announced the appointment of industry veteran Michael J. Grissinger to its Board of Directors, effective the same day. Grissinger brings more than two d...
Business Operations and StrategyProduct-Related Announcements
Lipocine Advances LPCN 1154 for Postpartum Depression
Positive
Jun 12, 2026
On June 12, 2026, Lipocine hosted a virtual key opinion leader event to highlight the unmet medical needs in postpartum depression and to present the clinical profile of its investigational therapy LPCN 1154. By convening experts to discuss this c...
Executive/Board ChangesShareholder Meetings
Lipocine Shareholders Approve Directors, Auditor and Incentive Plan
Positive
Jun 4, 2026
On June 3, 2026, Lipocine shareholders held their annual general meeting and elected four directors, including Dr. Mahesh V. Patel and three other nominees, to one-year terms, with no abstentions recorded in the director elections. Shareholders al...
Business Operations and StrategyProduct-Related Announcements
Lipocine Plans KOL Webinar on Oral PPD Candidate
Positive
Jun 4, 2026
On June 4, 2026, Lipocine announced it would host a virtual Key Opinion Leader webinar on June 12, 2026, to highlight unmet needs in postpartum depression and discuss the clinical profile of its investigational oral brexanolone candidate, LPCN 115...
Business Operations and StrategyProduct-Related Announcements
Lipocine Showcases Phase 3 Data in Postpartum Depression
Positive
May 26, 2026
On May 26, 2026, Lipocine presented Phase 3 clinical data for LPCN 1154, an oral formulation of brexanolone for the treatment of postpartum depression, at the American Society of Clinical Psychopharmacology Annual Meeting in Miami Beach, Florida. ...
Business Operations and StrategyProduct-Related Announcements
Lipocine Showcases Phase 3 Data for Postpartum Depression
Positive
May 19, 2026
On May 19, 2026, Lipocine announced that Phase 3 clinical data for LPCN 1154, its oral brexanolone candidate for postpartum depression, were accepted for both oral and poster presentations at the 2026 American Society of Clinical Psychopharmacolog...
Business Operations and Strategy
Lipocine Showcases Pipeline at Virtual Healthcare Conference
Positive
May 18, 2026
On May 18, 2026, Lipocine announced that its management would participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Company Showcase, scheduled for Wednesday, May 20, 2026, at 3:00 p.m. ET. The appearance underscores the compa...
Business Operations and StrategyRegulatory Filings and Compliance
Lipocine Updates Corporate Presentation for Investor Communications
Neutral
May 7, 2026
Lipocine disclosed that it has updated the corporate presentation it uses in meetings with investors, analysts and other stakeholders. The refreshed materials have been formally filed and are intended to guide ongoing discussions with the financia...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.